{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:41:35Z","timestamp":1768984895496,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anaplastic lymphoma kinase (ALK) inhibitors have been approved for patients with ALK-rearrangement lung cancer. The effect is superior to the standard first-line therapy of pemetrexed plus platinum-based chemotherapy. However, ALK inhibitors are associated with rare and sometimes fatal adverse events. Organizing pneumonitis (OP) is a rare and serious adverse event usually caused by ceritinib, and it is easily misdiagnosed as infectious pneumonia, metastasis, or cancer progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 56-year-old female presented with chest tightness and dyspnea for more than 10\u200adays. She was previously healthy with no significant medical history. Workup including chest computed tomography (CT), pathological examination of a biopsy specimen, and next-generation sequencing was consistent with a diagnosis of IVA ALK-rearrangement lung adenocarcinoma. She was treated with pemetrexed plus platinum-based chemotherapy and crizotinib concurrently, followed by maintenance therapy with crizotinib alone and she had an almost complete response. However, about 26\u200amonths after beginning treatment she developed multiple brain metastases. Crizotinib was discontinued and she was begun on ceritinib. After about 3\u200amonths the brain metastases had almost complete response. After 5\u200amonths of ceritinib, however, multiple patchy lesions appeared in the bilateral upper lungs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Treatment with antibiotics had no effect and blood and sputum cultures are negative. A CT-guided biopsy of the upper lung was performed, and pathological hematoxylin-eosin staining and immunohistochemical studies were consistent with OP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Ceritinib was discontinued, she was begun on prednisone 0.5\u200amg\/kg orally every day, and regular follow-up is necessary.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>CT of the chest 2 and 4\u200aweeks after beginning prednisone showed the lung lesions to be gradually resolving, and she was continued on prednisone for 2\u200amonths and gradually reduced the dose of prednisone every 2\u200aweeks. No related adverse events were occurred in patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>OP must be differentiated from infectious pneumonia, metastasis, or cancer progression. The mechanism of OP is still unknown and needs further research. Biopsy plays a role in making a diagnosis of OP. In our patient, discontinuing ceritinib and treating her with prednisone resulted in a good outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026449","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T15:02:41Z","timestamp":1625065361000},"page":"e26449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib"],"prefix":"10.1097","volume":"100","author":[{"given":"Yonghui","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiguo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiexia","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Pathology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-6142","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40261-019-00880-8","article-title":"Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer","volume":"40","author":"Li","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","article-title":"Phase 1\/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6","volume":"150","author":"Wu","year":"2020","journal-title":"Lung Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"100571","DOI":"10.1016\/j.currproblcancer.2020.100571","article-title":"Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India","volume":"44","author":"Patel","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a Phase III comparison of first-line crizotinib versus Chemotherapy in East Asian Patients with ALK-positive advanced non-small cell lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/jdi.13168","article-title":"Ceritinib-associated hyperglycemia in the Japanese adverse drug event report database","volume":"11","author":"Fujita","year":"2019","journal-title":"J Diabetes Investig"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2169\/internalmedicine.2597-18","article-title":"Acute interstitial lung disease induced by rechallenge with ceritinib","volume":"59","author":"Hotta","year":"2020","journal-title":"Intern Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11523-020-00733-x","article-title":"Ceritinib-induced organizing pneumonia in lung cancer: a retrospective analysis","volume":"15","author":"Choi","year":"2020","journal-title":"Target Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/cam4.659","article-title":"Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients","volume":"5","author":"Cui","year":"2016","journal-title":"Cancer Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/jcm9113543","article-title":"New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives","volume":"9","author":"de Mello","year":"2020","journal-title":"J Clin Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jjco\/hyy016","article-title":"Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset","volume":"48","author":"Kiura","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000200015","article-title":"Severe organizing pneumonia after two cycles of docetaxel as fourth-line chemotherapy for advanced non-small cell carcinoma of the lung","volume":"2","author":"Hasskarl","year":"2009","journal-title":"Case Rep Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/rmed.2000.0805","article-title":"Bronchiolitis obliterans-organizing pneumonia: an Italian experience","volume":"94","author":"Cazzato","year":"2000","journal-title":"Respir Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.21037\/apm-19-420","article-title":"Pneumonia caused by crizotinib: case report and review of literature","volume":"10","author":"Gou","year":"2021","journal-title":"Ann Palliat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:34:05Z","timestamp":1746336845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026449"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":20,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026449","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"2021-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}